Johnson & Johnson Starts Late-Stage Coronavirus Vaccine Clinical Trial

Johnson & Johnson (NYSE: JNJ) has moved into phase 3 development of its coronavirus vaccine candidate, which goes by the code name JNJ-78436735. The company trails Moderna (NASDAQ: MRNA), AstraZeneca (NYSE: AZN), and the duo of Pfizer (NYSE: PFE) and BioNTech (NASDAQ: BNTX), which are all in the process of finishing up enrollment in phase 3 clinical trials for their own COVID-19 vaccine candidates. It may also take Johnson & Johnson longer to reach full enrollment in its study given its larger size.